Press release
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December
About this update from Absci Corporation
[{"type":"text","content":"Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company’s ABS-201 (anti-PRLR) program for androgenetic alopecia. Additionally, Absci now expects to initiate the Phase 1/2a trial for this program in early December, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar to be hosted on December 11 will feature leading KOLs in the dermatology and hair loss fields, and highlight the clinical trial path, differentiated profile, and market potential of the ABS-201 program. KOLs presenting at this event include: Dr. David J. Goldberg, MD, JD, Clinical Professor of Dermatology at the Icahn School of Medicine at Mount SinaiMike Jafar, Medical Aesthetics ExecutiveDr. Ralf Paus, M.D., D.Sc., F.R.S.B., Research Professor of Dermatology and Cutaneous Surgery, University of Miami Miller School of MedicineDr. Anthony Rossi, MD, Attending Dermatologist, Memorial Sloan Kettering Cancer Center; Professor of Dermatology, Weill Cornell Medical CollegeDr. Rodney Sinclair, MBBS, MD, FACD, Professor of Dermatology at the University of Melbourne and Director of Sinclair Dermatology The webinar will begin at 10:00 a.m. Eastern Time and feature presentations on the latest developments and status of the ABS-201 program, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern Time. Interested parties may register for the seminar via this link, or access a live and archived webcast of the event on the company’s investor relations website at: investors.absci.com. About ABS-201 and Androgenetic Alopecia Androgenetic alopecia, commonly known as male-pattern or female-pattern hair loss, affects approximately 80 million Americans alone. The condition causes crown balding and receding hairlines in men, and progressive hair thinning in women. Currently, the only FDA-approved treatments – minoxidil and finasteride – show limited ef...